Department of Medicine, Division of Pulmonary and Critical Care Medicine, Center for Translational Medicine, Jane and Leonard Korman Lung Institute, Thomas Jefferson University, 1020 Locust St., Suite 543G JAH, Philadelphia, PA, 19107, United States.
Curr Opin Pharmacol. 2020 Apr;51:1-10. doi: 10.1016/j.coph.2020.03.004. Epub 2020 Apr 29.
Numerous G protein-coupled receptors (GPCRs) regulate multiple airway functions and play fundamental roles in normal and aberrant airway and lung physiology. Thus, GPCRs are prime candidates of targeting by disease therapeutics. The intriguing proton-sensing GPCR Ovarian cancer G-protein coupled receptor 1 (OGR1; aka GPR68) has recently been shown capable of regulating airway smooth muscle (ASM) contraction and proliferation. Although the study of OGR1 has been confounded by the fact that the proton is the presumed cognate ligand of OGR1, recent studies have begun to identify novel ligands and modulators capable of regulating the diverse signaling, and functional role of OGR1. Such studies offer hope for OGR1-targeting drugs as therapeutics for obstructive lung diseases such as asthma. Herein, we review the literature to date detailing the receptor biology and pharmacology of OGR1, receptor function in the airway, and describe the potential clinical utility of OGR1-modulating drugs.
许多 G 蛋白偶联受体 (GPCR) 调节多种气道功能,并在正常和异常气道及肺生理学中发挥基本作用。因此,GPCR 是疾病治疗药物的主要靶点候选物。最近的研究表明,令人感兴趣的质子感应 GPCR 卵巢癌 G 蛋白偶联受体 1 (OGR1;又名 GPR68) 能够调节气道平滑肌 (ASM) 收缩和增殖。尽管对 OGR1 的研究受到质子被认为是 OGR1 的同源配体这一事实的困扰,但最近的研究已经开始确定能够调节 OGR1 多样化信号转导和功能作用的新型配体和调节剂。这些研究为靶向 OGR1 的药物作为治疗哮喘等阻塞性肺疾病的药物带来了希望。本文综述了迄今为止详细描述 OGR1 的受体生物学和药理学、OGR1 在气道中的受体功能以及描述 OGR1 调节药物的潜在临床应用的文献。